Sodium–glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis

Peter S Hamblin, Rosemary Wong and Leon A Bach
Med J Aust 2020; 212 (7): . || doi: 10.5694/mja2.50525
Published online: 20 April 2020

Risk of SGLT2 inhibitor‐associated diabetic ketoacidosis in type 2 diabetes: some answers, but more questions

Prescribers have enthusiastically embraced sodium–glucose cotransporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes on the strength of accumulating data reporting improved cardiovascular and renal outcomes. In Australia, in 2016, 757 826 Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme prescriptions containing an SGLT2 inhibitor were dispensed. By 2019, that number had risen to 2.3 million.1 Assuming these scripts are dispensed monthly, an estimated 19% of all patients with type 2 diabetes (about 190 000 people) are currently being treated with SGLT2 inhibitors.

  • Peter S Hamblin1,2
  • Rosemary Wong3
  • Leon A Bach4,5

  • 1 Western Health, Melbourne, VIC
  • 2 University of Melbourne, Melbourne, VIC
  • 3 Box Hill Hospital, Melbourne, VIC
  • 4 Alfred Health, Melbourne, VIC
  • 5 Monash University, Melbourne, VIC


Competing interests:

Leon Bach was an investigator in the DECLARE study.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.